Business Description
Guanhao Biotech Co Ltd
NAICS : 339112
ISIN : CNE100001575
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.31 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | 3.34 | |||||
Interest Coverage | 44.36 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 6.8 | |||||
Beneish M-Score | -2.99 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.5 | |||||
3-Year EBITDA Growth Rate | -10.5 | |||||
3-Year EPS without NRI Growth Rate | -5.4 | |||||
3-Year FCF Growth Rate | -86.3 | |||||
3-Year Book Growth Rate | -10.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 48.91 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.21 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.33 | |||||
9-Day RSI | 52.32 | |||||
14-Day RSI | 53.42 | |||||
6-1 Month Momentum % | -15.15 | |||||
12-1 Month Momentum % | -30.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.79 | |||||
Quick Ratio | 1.31 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 321.72 | |||||
Days Sales Outstanding | 67.85 | |||||
Days Payable | 48.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 0.67 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.32 | |||||
Operating Margin % | 12.46 | |||||
Net Margin % | 5.33 | |||||
FCF Margin % | -11.45 | |||||
ROE % | 3.86 | |||||
ROA % | 2.98 | |||||
ROIC % | 3.19 | |||||
3-Year ROIIC % | 5.64 | |||||
ROC (Joel Greenblatt) % | 9.14 | |||||
ROCE % | 4.79 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 126.88 | |||||
Forward PE Ratio | 32.74 | |||||
PE Ratio without NRI | 78.68 | |||||
PS Ratio | 6.69 | |||||
PB Ratio | 5 | |||||
Price-to-Tangible-Book | 6.11 | |||||
Price-to-Operating-Cash-Flow | 45.94 | |||||
EV-to-EBIT | 103.78 | |||||
EV-to-EBITDA | 103.78 | |||||
EV-to-Revenue | 6.81 | |||||
EV-to-FCF | -56.74 | |||||
Price-to-Projected-FCF | 2.46 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Graham-Number | 4.61 | |||||
Price-to-Net-Current-Asset-Value | 24.76 | |||||
Earnings Yield (Greenblatt) % | 0.96 | |||||
FCF Yield % | -1.63 | |||||
Forward Rate of Return (Yacktman) % | 0.81 |